LAMATTINA JOHN L 4
4 · LIGAND PHARMACEUTICALS INC · Filed Nov 12, 2025
Insider Transaction Report
Form 4
LAMATTINA JOHN L
Director
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−2,145→ 0 totalExercise: $66.13Exp: 2027-05-25→ Common Stock (2,145 underlying) - Exercise/Conversion
Common Stock
2025-11-07$69.51/sh+2,034$141,383→ 32,758 total - Sale
Common Stock
2025-11-07$205.45/sh−2,145$440,690→ 30,724 total - Sale
Common Stock
2025-11-07$205.45/sh−2,034$417,885→ 30,724 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−2,034→ 0 totalExercise: $69.51Exp: 2026-05-23→ Common Stock (2,034 underlying) - Exercise/Conversion
Common Stock
2025-11-07$66.13/sh+2,145$141,849→ 32,869 total
Footnotes (2)
- [F1]This Option was previously reported as a Grant of 2,456 shares, which vested in full on May 25, 2018, at an exercise price of $113.5000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F2]This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.